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CLINICAL CANCER RESEARCH | CLINICAL TRIALS: IMMUNOTHERAPY

First-in-Human Phase I/II ICONIC Trial of the ICOS
Agonist Vopratelimab Alone and with Nivolumab:
ICOS-High CD4 T-Cell Populations and Predictors of
Response

ABSTRACT

◥

Purpose: The ﬁrst-in-human phase I/II ICONIC trial evaluated
an investigational inducible costimulator (ICOS) agonist, vopratelimab, alone and in combination with nivolumab in patients with
advanced solid tumors.
Patients and Methods: In phase I, patients were treated with
escalating doses of intravenous vopratelimab alone or with nivolumab. Primary objectives were safety, tolerability, MTD, and
recommended phase II dose (RP2D). Phase II enriched for
ICOS-positive (ICOSþ) tumors; patients were treated with vopratelimab at the monotherapy RP2D alone or with nivolumab.
Pharmacokinetics, pharmacodynamics, and predictive biomarkers
of response to vopratelimab were assessed.
Results: ICONIC enrolled 201 patients. Vopratelimab alone and
with nivolumab was well tolerated; phase I established 0.3 mg/kg
every 3 weeks as the vopratelimab RP2D. Vopratelimab resulted in
modest objective response rates of 1.4% and with nivolumab of

2.3%. The prospective selection for ICOSþ tumors did not enrich
for responses. A vopratelimab-speciﬁc peripheral blood pharmacodynamic biomarker, ICOS-high (ICOS-hi) CD4 T cells, was
identiﬁed in a subset of patients who demonstrated greater clinical
beneﬁt versus those with no emergence of these cells [overall
survival (OS), P ¼ 0.0025]. A potential genomic predictive biomarker of ICOS-hi CD4 T-cell emergence was identiﬁed that
demonstrated improvement in clinical outcomes, including OS
(P ¼ 0.0062).
Conclusions: Vopratelimab demonstrated a favorable safety
proﬁle alone and in combination with nivolumab. Efﬁcacy
was observed only in a subset of patients with a vopratelimabspeciﬁc pharmacodynamic biomarker. A potential predictive biomarker of response was identiﬁed, which is being prospectively
evaluated in a randomized phase II non–small cell lung cancer trial.
See related commentary by Lee and Fong, p. 3633
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Clinical beneﬁt with single-agent programmed death-1 receptor or
programmed death ligand-1 [PD-(L)1] inhibitors is limited to a
minority of patients. There has been a substantial increase in combination trials investigating novel immunotherapy agents in combination with PD-(L)1 inhibitors, but few have been successful (1, 2). One
approach to improve the value of these combination approaches is to
determine the contributory effects of each agent through the implementation of pharmacodynamic biomarkers. Another strategy is to
develop potential predictive biomarkers of response to identify
patients most likely to beneﬁt from the combination. The use of
established predictive biomarkers, such as PD-L1 IHC, microsatellite
instability (MSI)-high, and tumor mutational burden has contributed
to improved clinical outcomes with PD-(L)1 inhibitors (3). However,
there remains an unmet clinical need for the development of rational
and effective combination regimens and identiﬁcation of novel predictive biomarkers for the selection of appropriate patients for such
therapies (4).
The inducible costimulator (ICOS) of T cells is a member of the
B7/CD28/CTLA-4 immunoglobulin superfamily expressed largely
on T cells. Unlike CD28, which is constitutively expressed on T cells,
ICOS is upregulated following initial T-cell priming (5). Upon
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Translational Relevance

activation, ICOS induces a signal through the PI3K/protein kinase B
(AKT) pathway, resulting in the expression of lineage-speciﬁc transcription factors (e.g., T-bet, GATA-3) and subsequent T-cell proliferation and survival (6). Other T-cell costimulatory molecules such as
OX40, 4-1BB, CD40, and CD28 have been shown to require ICOS
signaling to exert their biological function, suggesting that ICOS
regulates a critical nexus of costimulatory activity (7–11). Signaling
through ICOS may also help overcome resistance to PD-(L)1–mediated T-cell exhaustion (12).
Signaling through ICOS leads to diverse effects on T-cell subsets,
including proliferation, differentiation, and survival of distinct ICOShigh (hi) CD4 T-cell populations. Induction of a population of ICOShi CD4 T cells occurs upon treatment with the CTLA-4 antibody
ipilimumab in PD-(L)1 inhibitor–na€ve patients, and importantly,
persistence of this T-cell population was associated with improved
overall survival (OS) in patients with PD-1 inhibitor–na€ve melanoma
treated with ipilimumab (13). In preclinical models, treatment with
ICOS agonist antibodies in vivo induced tumor regression in multiple
tumor models and promoted long-term immunity (14). This antitumor activity was further enhanced in combination with anti-PD-1,
suggesting ICOS agonist antibodies may enhance the effects of
anti-PD-1 when administered in combination (14). In addition,
ICOS antibody treatment led to an increase in frequency of CD8 T
cells within mouse tumors; PD-(L)1 inhibitors restore effector CD8
T-cell activity, thus providing strong rationale for combining with
a costimulator, such as an ICOS agonist (14).
Vopratelimab (JTX-2011) is an investigational potential ﬁrst-inclass humanized IgG1k agonist mAb that speciﬁcally binds to ICOS
and is designed to augment an antitumor immune response (15). The
mechanism of action of vopratelimab requires the initial priming of
T cells followed by upregulation of ICOS expression on the cell surface
of CD4 T cells, after which vopratelimab engagement results in their
proliferation and sustained activation (14).
ICONIC, a phase I/II, open-label, multicenter, ﬁrst-in-human
(FIH) clinical trial, investigated the safety, tolerability, pharmacokinetics, pharmacodynamics, recommended phase II dose (RP2D), and
preliminary efﬁcacy of vopratelimab as monotherapy and in combination with nivolumab, as well as potential predictive biomarkers of
response to therapy. Here we present the ﬁrst publication of the
ICONIC trial and detail how a pharmacodynamic biomarker for
vopratelimab led to the identiﬁcation of a potential predictive bio-
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Patients and Methods
Study design
This four-part, adaptive phase I/II, open-label, multicenter, FIH
trial was designed to evaluate the safety and tolerability, determine the
MTD and RP2D, as well as the preliminary efﬁcacy of the ICOS agonist
mAb vopratelimab (JTX-2011) as monotherapy, and in combination
with nivolumab in adult patients with advanced solid tumors
(NCT02904226). Phase I was a classical 3þ3 dose escalation that
assessed escalating doses of vopratelimab (0.003–1.0 mg/kg) as monotherapy (part A) or in combination with ﬁxed doses of nivolumab (part
B). Parts A and B also included expansion cohorts (AP1, AP2, BP1,
BP2) to further explore safety/pharmacokinetic/pharmacodynamic
markers of vopratelimab alone and in combination with nivolumab.
In phase II, vopratelimab efﬁcacy alone and in combination with
nivolumab was investigated in speciﬁc tumors. Preclinical data suggested a high ICOS IHC score would be required for the optimal
clinical beneﬁt of an ICOS agonist; therefore, tumor types were selected
on the basis of higher intratumoral ICOS expression. Vopratelimab
treatment (part C) was assessed in PD-(L)1 inhibitor experienced head
and neck squamous cell carcinoma (HNSCC) and NSCLC, PD-(L)1
inhibitor-na€ve or experienced gastric or gastroesophageal junction
cancer and PD-(L)1 inhibitor-na€ve or experienced triple-negative
breast cancer (TNBC), as well as other advanced solid tumors.
Combined treatment with vopratelimab and nivolumab (part D) was
assessed in PD-(L)1 inhibitor experienced HNSCC and NSCLC, and
PD-(L)1 inhibitor na€ve and experienced TNBC and gastric or gastroesophageal junction cancer. PD-(L)1 inhibitor–experienced tumors
were deﬁned as cancers that have progressed on or after therapy with a
PD-1 or PD-L1 inhibitor.
Part C enriched for patients with medium to high ICOS expression
per IHC score in archival tumor, with ICOS levels reassessed on a fresh
pretreatment biopsy. At least 10 patients with ICOS-hi tumors by IHC
on a fresh biopsy and at least 5 patients with ICOS-low (ICOS-lo)
tumors by IHC on a fresh biopsy were required in each part C cohort.
Part D enrolled indications anticipated to have ICOS-positive tumors
(NSCLC, HNSCC, gastric, and TNBC). ICOS expression levels vary
within these indications; therefore, patients were stratiﬁed for ICOS
expression.
Both phases examined the correlation between potential predictive
biomarkers of response and efﬁcacy [response rate, duration of
response (DoR), disease control rate (DCR), landmark progressionfree survival (PFS) rate, PFS, landmark OS rate, and OS] as exploratory
objectives.
Patients
Patients were enrolled from 16 sites in North America from August
2016 to May 2018. All were required to have evaluable or measurable
disease, according to RECIST v1.1, with at least one measurable lesion.
All enrolled patients were ≥18 years of age, had an Eastern Cooperative
Oncology Group performance status ≤1, and a predicted life expectancy ≥3 months. Measurable disease was required for phase II.
Dose-escalation cohorts included patients with advanced and/or
refractory, non-hematologic, extracranial malignancy with disease
progression after treatment with all available therapies known to
confer clinical beneﬁt. For phase II cohorts, patients must have
progressed on or after all approved therapies. Patients who were
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ICONIC demonstrated that vopratelimab, an inducible costimulator (ICOS) agonist mAb, was well tolerated alone and with
nivolumab in patients with advanced solid tumors. Vopratelimab
did not confer durable, antitumor activity nor did its combination
with nivolumab improve efﬁcacy in the majority of patients with
advanced solid tumors. The prospective selection of patients with
ICOS-positive tumors did not enrich for antitumor responses.
However, reverse translational studies led to the identiﬁcation of
the emergence of peripheral ICOS-high CD4 T cells as a vopratelimab-speciﬁc pharmacodynamic biomarker. Furthermore, a
potential predictive biomarker of response to vopratelimab alone
and with a PD-1 inhibitor, comprising an RNA-based tumor
inﬂammation signature with a speciﬁc threshold, was also identiﬁed. These ﬁndings are being prospectively validated in a randomized phase II non–small cell lung cancer trial.

marker that is now being assessed prospectively in a phase II non–
small cell lung cancer (NSCLC) clinical trial (SELECT,
NCT04549025).

The ICOS Agonist Vopratelimab Alone and with Nivolumab

receiving concurrent anticancer treatment, had refused standard
therapy, were immunodeﬁcient, were receiving immunosuppressive therapy, or had undergone major surgery <6 weeks prior to the
ﬁrst data of study treatment, were excluded. Further information
regarding inclusion and exclusion criteria is available at clinicaltrials.gov (NCT02904226). The study was conducted in accordance
Good Clinical Practice guidelines deﬁned by the International
Conference on Harmonization. Approval was obtained from independent ethics committees and Institutional Review Boards at all
participating centers and all patients provided informed written consent prior to participation based on the principles of the
Declaration of Helsinki.

Efﬁcacy assessment
Antitumor activity was investigator assessed using RECIST v1.1,
and imaging for efﬁcacy assessments was performed approximately
every 9 weeks by CT. PFS (per RECIST 1.1 investigator assessment)
was deﬁned as the number of months from the date of ﬁrst dose to the
date of death or documented (objective) disease progression via
RECIST v1.1 by investigator assessment, whichever occurred sooner.
OS was deﬁned as the interval of time from ﬁrst dose date to the date of
death for any cause.
Pharmacokinetics of vopratelimab and nivolumab
Blood samples were collected for vopratelimab concentration determinations during cycle 1 prior to dosing, at 0.5, 1, 1.5 (vopratelimab
monotherapy), or 2.5 (vopratelimab in combination with nivolumab),
4 and 6 hours postdose, and 2, 8, and 15 days postdose. For subsequent
cycles, samples were collected predose and 1 hour postdose. All times
were relative to the start of the vopratelimab infusion times. Blood
samples for nivolumab concentration determinations were collected at
the same timepoints as for vopratelimab.
Vopratelimab concentrations were quantiﬁed in serum using a
validated electrochemiluminescent assay. Brieﬂy, vopratelimab was
captured on meso scale discovery (MSD) plates coated with a mouse
anti-human vopratelimab mAb. Detection was via the same mAb
conjugated to ruthenium. The assay was validated to a lower limit of
quantitation (LLOQ) of 750 pg/mL.
Nivolumab concentrations were measured in serum using a validated ELISA. Brieﬂy, nivolumab was captured on 96-well plates coated
with either PD-1-human IgG1 fusion protein or his-tagged recombinant PD-1 protein and detected using a mouse anti-human IgG4 mAb
conjugated to horseradish peroxidase (HRP). The assay was validated
to an LLOQ of 100 ng/mL.

AACRJournals.org

Samples analyzed for immunophenotyping studies
Blood collections and peripheral blood mononuclear cell (PBMC)
processing from clinical samples were performed at clinical sites.
Patient blood was collected directly into 8 mL sodium heparin CPT
tubes using a BD vacutainer safety-lok blood collection system and
processed according to manufacturer’s instructions with the following
modiﬁcations. Immediately after collection the CPT tube was gently
inverted 10 times to mix the anticoagulant with the blood. CPT tubes
were then spun at 1,800  g for 15 minutes at 22 C in a swing bucket
centrifuge, cell and plasma fractions were then decanted into a 15 mL
Falcon tube and spun at 300  g for 15 minutes at 22 C. Supernatant
was decanted, and the cell pellet was resuspended in 1 mL freezing
media (10% FBS in DMSO) and transferred via pipet to a 1.8 mL
cryovial. Cryovials were immediately placed in a room temperature
Mr. Frosty (Thermo Fisher Scientiﬁc) or CoolCell (Corning) and
stored overnight in a 80 C freezer and then shipped directly to
Jounce or FlowMetric packed in dry ice. Upon arrival to Jounce or
FlowMetric, cryovials were immediately stored at 80 C until ﬂow
cytometry analysis.

Clin Cancer Res; 28(17) September 1, 2022

Downloaded from http://aacrjournals.org/clincancerres/article-pdf/28/17/3695/3199454/3695.pdf by Washington University St Louis user on 30 October 2022

Interventions
Patients were treated with vopratelimab monotherapy (JTX-2011;
a humanized IgG1k mAb and ICOS agonist; Jounce Therapeutics,
Inc.), or vopratelimab in combination with nivolumab (OPDIVO;
a human IgG4k anti-PD-1 mAb; Bristol-Myers Squibb). All study
drugs were administered intravenously every 3 weeks.
In the dose escalation (parts A and B), vopratelimab monotherapy
was dosed from 0.003 mg/kg escalating to 1.0 mg/kg; nivolumab was
dosed at 240 mg i.v. every 3 weeks. Vopratelimab in combination with
nivolumab was dosed from 0.01 mg/kg escalating to 0.3 mg/kg. Dose
escalation was approved by a Safety Monitoring Committee composed
of investigators and sponsor representatives at each stage. In the phase
II efﬁcacy cohorts (C and D), vopratelimab was administered at the
RP2D determined from the phase 1 dose escalation (0.3 mg/kg i.v.
every 3 weeks), and nivolumab was administered at 240 mg/kg i.v.
every 3 weeks.

Samples for vopratelimab anti-drug antibodies (ADA) and neutralizing ADA were collected predose on day 1 of each cycle. ADA
to vopratelimab were detected via an electrochemiluminescent
assay using a three-tier procedure that consisted of screening
without added vopratelimab, screening with added vopratelimab
to conﬁrm speciﬁcity, and serial dilution of positive samples to
determine the titer. Brieﬂy, clinical samples or controls were diluted
1:50 into acetic acid to disrupt existing ADA/drug complexes, then
incubated with a neutralizing solution containing biotinylated
vopratelimab (bt-vopratelimab) and ruthenium-labeled vopratelimab (ru-vopratelimab). For speciﬁcity screening and titering, unlabeled vopratelimab was also included in the assay solution.
Bridging complexes of bt-vopratelimab-ADA-ru-vopratelimab
were captured on streptavidin-coated plates and ru-vopratelimab
was quantitated by electrochemiluminescence. Samples testing
positive in both screening steps were considered positive and corresponding titers were determined by serial dilution and reported.
Otherwise, samples were reported as negative.
ADA-positive samples were further assayed for neutralizing activity. Brieﬂy, samples were acid treated, then incubated with btvopratelimab in a neutralizing buffer. The resulting complexes were
captured on a streptavidin-coated plate, washed, and then acid treated
to dissociate ADA. The acid-treated samples were incubated with ruvopratelimab in neutralizing buffer, transferred to an MSDstreptavidin plate coated with biotin-conjugated ICOS to capture
uncomplexed ru-vopratelimab. Captured ru-vopratelimab was quantitated by electrochemiluminescence. A maximal signal was observed
in absence of neutralizing ADA, and the amount of neutralizing
activity was estimated on the basis of the decline in signal.
Pharmacokinetic parameters were calculated for vopratelimab and
nivolumab for cycle 1 by noncompartmental analysis using Phoenix
WinNonlin (v. 8.2). Cmax, Ctrough, and the AUC from the start of dosing
to the last measured timepoint (AUClast) were calculated for all
patients. For patients treated with nivolumab, the AUC from dosing
through day 14 was also calculated for comparison with historical data
for nivolumab administered every 2 weeks. When the data were
adequate to estimate the terminal elimination half-life, half-life values
were also reported for vopratelimab. Actual sampling times were used
for the analysis. Cmax, Ctrough, and AUC values were summarized by
geometric mean and geometric coefﬁcient of variation. Half-life was
summarized by arithmetic mean and SD.
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ICOS-hi versus ICOS-lo emergence criteria
Peripheral CD4 T cells were identiﬁed as ICOS-hi or ICOS-lo based
on predetermined ﬂow cytometry parameters that were established
individually for each subject at baseline. ICOS-hi and ICOS-lo gates
were drawn based on isotype stain and baseline samples, respectively.
Mean ﬂuorescence intensity (MFI) and % of CD4 T cells above baseline
were reported for each sample. For a subject to be classiﬁed as “ICOShi,” ≥5% of ICOS-stained cells had to exhibit a ≥1.5-fold increase over
baseline MFI for at least one postdose visit. A patient was placed in the
ICOS-lo group if they did not meet the criteria for ICOS-hi and had at
least one evaluable peripheral blood CD4 T-cell sample postbaseline.
Emergence of ICOS-hi CD4 T cells was observed mid-way through the
study with most samples analyzed retrospectively. Samples were
collected at speciﬁc visits outlined in the study protocol though
evaluable samples were not available at every timepoint.

Analysis of gene expression using NanoString
Four slices from each pretreatment formalin-ﬁxed parafﬁnembedded tumor block were cut and used for RNA extraction using
the High Pure RNA Parafﬁn Kit (catalog no. 03 270 289 001, Roche) as
per the manufacturer’s recommendations. Quality and quantity were
observed with the 5200 Fragment Analyzer system (Agilent Technologies Inc.) in conjunction with the highsensitivity RNA Kit (15NT;
catalog no. DNF-472, Agilent Technologies Inc.). If sufﬁcient RNA was
present, 50 ng of RNA was processed according to the manufacturer’s
instructions for the NanoString nCounter workﬂow (two reactions
contained 45 and 30 ng, due to low yield). All samples were evaluated
using a custom-designed base sequence (Jounce Therapeutics, Inc.),
nCounter panel, as well as custom-designed indication-speciﬁc spikein panels, where appropriate. Samples were proﬁled on an nCounter
SPRINT Proﬁler (NanoString Technologies Inc.).

IHC for ICOS and PD-L1 predictive biomarkers
PD-L1 and ICOS levels were evaluated in archival and pretreatment
tumor biopsies by NeoGenomics Laboratories Inc. ICOS was reported
by a score of 0, 1, 2 or 3, while PD-L1 was evaluated using a tumor
proportion score.
For the detection of ICOS, samples were baked for 1 hour at 60 C.
The slides were then processed on an automated IHC stainer (BOND,
Leica Biosystems). Brieﬂy, slides were dewaxed, incubated in 100%
alcohol, and rinsed in wash buffer. Antigen retrieval was performed
using the BOND ER2 solution at 100 C for 25 minutes. Slides were
rinsed in wash buffer, followed by a peroxide block for 10 minutes, and
then rinsed again in wash buffer. A protein block was then applied for
30 minutes, followed by 0.5 mg/mL anti-ICOS (clone M13) for an
additional 30 minutes. Slides were then rinsed in wash buffer, followed
by protein block for another 30 minutes. Slides were incubated with
postprimary antibody (Leica) for 8 minutes, then rinsed in wash
buffer, followed by incubation in HRP polymer for 8 minutes. Slides
were rinsed in wash buffer, followed by deionized water, and then in

Patient samples utilized for gene expression (tumor
inﬂammation signature) evaluation
Data from fresh pretreatment biopsies from 89 patients that passed
NanoString’s quality control described above were assessed: 29
patients were treated with vopratelimab monotherapy, while 60 were
treated with vopratelimab in combination with nivolumab. Tumor
samples obtained were from the safety/pharmacokinetic/pharmacodynamic expansion cohorts AP1/AP2 (n ¼ 8) and BP1/BP2 (n ¼ 14)
and phase II efﬁcacy cohorts C (n ¼ 21) and D (n ¼ 46). See
Supplementary Fig. S10 for disposition of tumor tissue samples
analyzed for tumor inﬂammation signature (TIS).
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Evaluation of gene expression data—TIS scores
Raw .RCC ﬁles were submitted to NanoString Technologies, Inc.,
data analysis service, to calculate the TIS score. All 28 genes (18
immune and 10 housekeeping) were included in the Jounce custom
nCounter panel. Scores were calculated by normalizing to TIS reference sample (in vitro transcripts speciﬁc for each TIS genes of a known
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Immunophenotyping of PBMC samples
ICOS-hi CD4þ T-cell immunophenotyping
PBMCs were counted and 1  106 cells were resuspended in ﬂow
buffer (PBSþ2% FBS, 1 mmol/L EDTA, and 0.1% sodium azide)
containing CD3-APC-H7 (clone SK7, BD Biosciences) and CD4PerCP-Cy5.5 antibodies (clone L200, BioLegend) for 30 minutes at
4⁰C. After washing with ﬂow buffer, cells were permeabilized and ﬁxed
using the FOXP3 Fixation/Permeabilization Concentrate and Diluent
Kit (eBioscience) according to the manufacturer’s instructions. Permeabilized cells were stained with biotinylated anti-human ICOS
antibody (clone: M13, Jounce Therapeutics, a noncompetitive binder
to ICOS compared with vopratelimab) for 30 minutes at 4 C. After
washing, cells were incubated with streptavidin-PE (BioLegend) for
30 minutes at 4 C, washed and then resuspended in ﬂow buffer. In
some experiments, Tbet-BV421 (clone 4B10, BioLegend) was added at
the intracellular staining step.
Flow cytometry was performed on the same day using the
FACSCanto II or LSR Fortessa (BD).
After January 2019, all clinical samples were analyzed at FlowMetric.
The same method, ﬂow panel, and analysis were followed at both Jounce
and FlowMetric.

3,30 -diaminobenzidine chromogen solution for 10 minutes. Slides
were rinsed in deionized water, then incubated with hematoxylin
counterstain for 7 minutes. Slides were then rinsed in deionized water,
followed by wash buffer, and then deionized water again. Slides were
dehydrated through graded alcohol and xylene, prior to applying
coverslips. All reagents were provided by Leica Biosystems, Germany
unless otherwise stated.
For the detection of PD-L1, the 22C3 PharmDX assay was utilized
using an Autostainer Link 48. Brieﬂy, slides were incubated in target
retrieval solution for 20 minutes at 97 C, followed by cooling to 65 C.
Slides were then incubated in EnVision FLEX Wash Buffer at room
temperature for 5 minutes, and transferred to the autostainer for the
automated PD-L1 IHC 22C3 protocol. Once staining was complete,
the slides were counterstained with EnVision FLEX Hematoxylin
(Agilent-DAKO), prior to applying coverslips. All equipments, kits,
and reagents were provided by Agilent Technologies, Inc, unless
otherwise stated.
For both IHC assays, appropriate controls were used to evaluate
assay performance. For ICOS, this included both positive and negative
cell lines, as well as a positive tonsil tissue. For PD-L1, control tissues
were utilized as indicated in the 22C3 PharmDX assay manual (Dako,
Agilent Technologies, Inc.), including gastric adenocarcinoma or
NSCLC as appropriate. For indications not covered by the 22C3
PharmDX assay manual, controls included universal laboratory controls (placenta, smooth muscle), along with the PD-L1 IHC 22C3
Control Cell Line Slides (Dako, Agilent Technologies, Inc.).

In a companion study, cryopreserved PBMC samples from
anti-PD-1/L1 inhibitor monotherapy-treated patients were purchased from Discovery Life Sciences. Upon receipt, all samples were
stored at 80 C until ﬂow cytometry analysis.

The ICOS Agonist Vopratelimab Alone and with Nivolumab

concentration), followed by housekeeping genes and applying weights
speciﬁed in (16). Only samples that passed NanoString’s signal quality
control were included in further analysis.
Individual genes were evaluated for their ability to predict the
emergence of the pharmacodynamic biomarker. Raw gene expression
data were processed by removing poor quality samples, then normalizing the remaining samples to housekeeping genes. Genes that were
measured across all samples were included in analysis. Gene expression was compared between the group of patients who showed
emergence of ICOS-hi CD4þ T cells and the group of patients who
did not display the emergence of this population.

Predictive biomarker assessment
TIS score, PD-L1 IHC, and ICOS IHC based on pretreatment tumor
samples, and ICOS IHC and PD-L1 IHC based on archival tumor
samples were evaluated for their suitability as predictive biomarkers
for pharmacodynamic response (ICOS-hi CD4þ T-cell emergence)
and efﬁcacy response in patients treated with vopratelimab monotherapy or vopratelimab and nivolumab combination therapy. Details
of assessment methods can be found in the Statistical analysis section.
Statistical analysis
Results are summarized via summary statistics (number, mean,
median, SD, quartiles, minimum, maximum for continuous endpoints; number and percent for binary and categorical endpoints).
The correlation between efﬁcacy and potential predictive biomarkers
was explored to generate hypotheses for further testing. All data
analyses were conducted using the SAS System (SAS Institute, Inc.,
RRID: SCR_008567) Version 9.4. Volcano plots, box plots and IHC
histograms were plotted using TIBCO Spotﬁre version 7.11.1.0.12.
For the evaluation of gene expression data, statistics were calculated
in R ; speciﬁcally, t tests were performed using the “t.test” function,
and nominal P values, adjusted P values (using the Benjamini–
Hochberg method) and average fold changes were calculated.

{R: A Language and Environment for Statistical Computing},
author ¼ {{R Core Team}}, organization ¼ {R Foundation for Statistical Computing}, address ¼ {Vienna, Austria}, year ¼ {2018}, url ¼
{https://www.R-project.org/}
Detailed statistics for predictive biomarkers
ROC curves were used to evaluate the ability of biomarkers to
predict ICOS-hi CD4þ T-cell emergence. The ROC curves for each
biomarker were plotted with the true positive rate (sensitivity) against
the false positive rate (1  speciﬁcity) using all observed values as cutoff values. AUC was also calculated for a measure of the average
accuracy for the biomarker prediction. Youden Index was calculated
for each ROC curve over the possible cut-off values as follows: Youden
index ¼ Sensitivity þ Speciﬁcity  1 (the cut-off value which maximizes Youden index was chosen as the best cutoff). After a predictive
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Sample size
For the dose-escalation studies, the exact sample size was not
predetermined because of the dynamic nature of the classical 3þ3
design. For phase II tumor-speciﬁc expansion cohorts, a group
sequential design was considered for sample size determination
[Jennison and Turnbull, 2000. reference: Group Sequential Methods
with Applications to Clinical Trials (Chapman & Hall/CRC Interdisciplinary Statistics) 1st Edition]. A 90% power at a two-sided a of 5%
was designed to be achieved for the hypothesis testing by enrolling
approximately 15 patients per cohort (no more than 2% of b spent at
interim) as the ﬁrst step, and a potential expansion up to approximately 49 patients per cohort if the futility boundary is passed on the
basis of the results from the ﬁrst 15 patients for each cohort.
Part D (vopratelimab þ nivolumab) opened to enrollment shortly
after part C (vopratelimab monotherapy). Patients were preferentially
enrolled into the combination cohort for a total of 100 patients in part
D. Lack of efﬁcacy was observed with vopratelimab as a single agent,
hence part C was closed to enrollment after a total of 30 patients.
Data availability
All data relevant to the article are contained within the main and
Supplementary Data. Source/raw data for transcriptomic analysis are
available upon request.

Results
A total of 201 patients with various advanced solid tumors who
progressed on or after all approved therapies were enrolled and treated
with either vopratelimab monotherapy or vopratelimab in combination with nivolumab on the ICONIC trial. As shown in Table 1,
patients received a median of three prior lines of therapy in the
metastatic setting (range, 0–12) and all were included in the safety
analysis set (Supplementary Fig. S1); 187 (93%) patients met the
criteria to be considered evaluable for efﬁcacy (Supplementary
Fig. S1) as they completed a baseline tumor assessment and either
had at least one postbaseline tumor assessment scan and/or discontinued treatment due to death or disease progression. A total of 167
(83%) of these evaluable patients had at least one on-treatment tumor
assessment.
In the phase I dose-escalation portion, 71 patients were enrolled and
treated with vopratelimab alone (n ¼ 40) or in combination with
nivolumab (n ¼ 31) at escalating doses of 0.003, 0.01, 0.03, 0.1, 0.3, and
1 mg/kg every 3 weeks. In phase II, 130 patients were enrolled and
treated with vopratelimab alone (n ¼ 30) or in combination with
nivolumab (n ¼ 100). In phase II, vopratelimab was administered
intravenously at 0.3 mg/kg every 3 weeks, the RP2D deﬁned during
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Gene expression proﬁling of ICOS-hi CD4þ T cells
Transcriptional proﬁles of peripheral blood CD4þ T cells from
patients who demonstrated emergence of ICOS-hi CD4þ T cells were
compared with CD4þ T cells from representative cancer patient
samples in which ICOS-hi CD4 T cells were not detected. From these
samples, CD4þ T cells were separated by magnetic columns, and total
RNA was extracted and processed using the nCounter Human Immunology Panel (NanoString Technologies Inc). Differential gene expression was compared between vopratelimab patients and donor samples
by unpaired t tests and corrected for FDS using the Benjamini–
Hochberg procedure.

biomarker and its cutoff were chosen using ROC curve and Youden
index as above, efﬁcacy evaluations were provided by biomarker
subgroups as separated by the cutoff (e.g., TIS positive and TIS negative
subgroups).
Waterfall plots were used to display maximum percent change
from baseline in tumor measurements (measurements in sum of
diameters of target tumors) with colors indicating biomarker subgroups. Swimmer plots of time on treatment were also provided
for patients who were evaluated for TIS score with separate panels
for patients who are TISvopra positive and TISvopra negative. Estimates
of PFS and OS were summarized using the Kaplan–Meier method
(17), with median and corresponding two-sided 95% conﬁdence
interval (CI) by biomarker subgroups (predictive biomarker selected using steps above).

3699

Yap et al.

Table 1. Patient demographics (data cutoff: 07-22-2020).

ICONIC patient characteristics

Vopratelimab þ nivolumab
Total
n ¼ 131 (%)

64.0 (23.8–81.1)
35 (50.0)
35 (50.0)
51 (72.9)
13 (18.6)
6 (8.6)
3.0
56 (80.0)
32 (45.7)
14/32 (20.0)

60.0 (28.9–85.3)
73 (55.7)
58 (44.3)
99 (75.6)
19 (14.5)
13 (9.9)
3.0
83 (63.4)
67 (51.1)
25/67 (19.1)

Gastric n ¼ 10 (14.3)
NSCLC n ¼ 7 (10.0)
TNBC n ¼ 8 (11.4)
HNSCC n ¼ 6 (8.6)
Other n ¼ 39 (55.7)
Bile duct n ¼ 1, bladder n ¼ 1, breast n ¼ 1,
cholangiocarcinoma n ¼ 1, colon n ¼ 4,
endometrial n ¼ 4, HNSCCa n ¼ 5, melanoma n ¼ 4,
neuroendocrine n ¼ 1, origin unknown n ¼ 1,
ovarian n ¼ 2, pancreatic n ¼ 2, peritoneum n ¼ 1,
prostate n ¼ 2, rectal n ¼ 2, renal n ¼ 2, sarcoma n ¼ 4,
TNBCa n ¼ 1

Gastric n ¼ 35 (26.7)
NSCLC n ¼ 17 (13.0)
TNBC n ¼ 29 (22.1)
HNSCC n ¼ 26 (19.8)
Other n ¼ 24 (18.3)
Breast n ¼ 2, cervical n ¼ 2, colon n ¼ 4,
endometrial n ¼ 3, HNSCCa n ¼ 3,
melanoma n ¼ 3, ovarian n ¼ 1,
pancreatic n ¼ 1, prostate n ¼ 1,
rectal n ¼ 2, sarcoma n ¼ 2

Abbreviations: HNSCC, head and neck squamous cell carcinoma; NSCLC, non–small cell lung cancer; SD, standard deviation; TNBC, triple-negative breast cancer.
a
These HNSCC and TNBC tumors were evaluated for efﬁcacy with “Other.”

phase I based on safety, pharmacokinetics, and sustained target
engagement through the 3-week dosing period (see Pharmacokinetics,
immunogenicity, and receptor occupancy of vopratelimab section).
Safety and tolerability
Vopratelimab administered as monotherapy and in combination
with nivolumab was well tolerated in both the phase I and phase II
portions of the study. The dose escalation established a MTD of
0.3 mg/kg i.v. every 3 weeks for vopratelimab, after two dose-limiting
toxicities (DLT) were observed at 1.0 mg/kg, one dose level above the
RP2D. The DLTs were assessed as being inﬂammatory and consistent
with the mechanism of action of vopratelimab; these included a grade 3
aspartate aminotransferase (AST)/alanine aminotransferase elevation,
which resolved with steroids within 72 hours and a grade 3 rapid
worsening of a pleural effusion that was present at baseline.
Of the patients treated with vopratelimab monotherapy, 96% experienced a grade 1–2 treatment-emergent adverse event (TEAE), while
56% experienced grade 3–4 (Supplementary Table S1). The most
common grade 3–4 TEAEs observed included: anemia (11.4%), hyponatremia (8.6%), diarrhea (5.7%), and elevated AST levels (5.7%). A total
of 97% of those treated with vopratelimab and nivolumab experienced
a grade 1–2 TEAE, while 48% experienced grade 3–4. The most frequent grade 3–4 TEAEs observed with combination treatment included hyponatremia (9.9%), anemia (5.3%), elevated AST (4.6%), and
increased blood bilirubin (4.6%; Supplementary Table S1).
As listed in Table 2, grade 1–2 treatment-related AEs (TRAEs)
were observed in 61% of patients receiving vopratelimab monotherapy, the most common being fatigue (13%), decreased appetite
(10%), nausea (8.6%) and infusion-related reaction (8.6%). Grade
3–4 TRAEs were observed in 14% and included diarrhea (4.3%),
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anemia (4.3%), and increased AST (2.9%). In patients who received
combination therapy, 76% experienced grade 1–2 and 11.5%
grade 3–4. The most common grade 1–2 TRAEs were nausea
(21.4%), infusion-related reaction (19.1%), fatigue (17.6%) and
decreased appetite (13.7%). The most common grade 3–4 TRAEs
included increased AST (3.1%), hyponatremia (1.5%), maculopapular rash (0.8%), and abdominal pain (0.8%).
In ICONIC, 12.9% of patients treated with vopratelimab monotherapy experienced an immune-related AE (irAE) while 25.5% of
patients treated with vopratelimab plus nivolumab reported an irAE.
The most common were anemia and rash for both vopratelimab
alone and with nivolumab, and all cases were mild to moderate. No
signiﬁcant irAEs were observed as they relate to anemia, hyponatremia, or other endocrinopathies.
Because vopratelimab is an IgG1 molecule, analysis of peripheral
blood immune cell subsets to rule out immune cell depletion was
included in the safety evaluation, and no signiﬁcant changes were
observed in CD4 T effector cells, CD4 regulatory T cells, CD8 T cells, or
natural killer cells (Supplementary Fig. S2).
Pharmacokinetics, immunogenicity, and receptor occupancy of
vopratelimab
Pharmacokinetic parameters, calculated by noncompartmental
analysis after the ﬁrst dose of vopratelimab from the phase I dose
escalation and expansion cohorts, are summarized in Supplementary
Table S2. Target-mediated drug disposition was apparent at doses
below 0.03 mg/kg. The appearance of both ADA and neutralizing
ADA were transient in many patients, not dose dependent, and
there was no apparent effect of ADA or neutralizing ADA on the
pharmacokinetics of vopratelimab. Speciﬁcally, treatment-induced

CLINICAL CANCER RESEARCH

Downloaded from http://aacrjournals.org/clincancerres/article-pdf/28/17/3695/3199454/3695.pdf by Washington University St Louis user on 30 October 2022

Age (yrs), median (range)
Male
Female
Caucasian
Non-Caucasian
Not reported or missing
Prior therapies, median
≥3 prior therapies, n (%)
Prior immunotherapy, n (%)
Refractory to prior immunotherapy
(best overall response of progressive
disease), n (%)
Tumor type, n (%)

Vopratelimab monotherapy
Total
n ¼ 70 (%)

The ICOS Agonist Vopratelimab Alone and with Nivolumab

Table 2. TRAEs (data cutoff: 07-22-2020).

Preferred term

43
6
9
6
7
4
4
1
4
6
4
1
1
1
0
2
1
0
3
0
0
4
2
0
0
0
1
1
0
2
1
1
1

(61.4)
(8.6)
(12.9)
(8.6)
(10.0)
(5.7)
(5.7)
(1.4)
(5.7)
(8.6)
(5.7)
(1.4)
(1.4)
(1.4)
(2.9)
(1.4)
(4.3)

(5.7)
(2.9)

(1.4)
(1.4)
(2.9)
(1.4)
(1.4)
(1.4)

10 (14.3)
0
0
1 (1.4)
0
0
0
2 (2.9)
3 (4.3)
0
0
0
0
0
0
1 (1.4)
0
0
3 (4.3)
0
0
0
0
0
0
1 (1.4)
0
0
0
0
0
0
0

Vopratelimab þ nivolumab
N ¼ 131 (%)
Grade 1 and 2
Grade ≥3
n (%)
n (%)
100 (76.3)
28 (21.4)
23 (17.6)
25 (19.1)
18 (13.7)
11 (8.4)
11 (8.4)
6 (4.6)
9 (6.9)
5 (3.8)
7 (5.3)
8 (6.1)
8 (6.1)
7 (5.3)
8 (6.1)
4 (3.1)
6 (4.6)
7 (5.3)
1 (0.8)
4 (3.1)
5 (3.8)
1 (0.8)
3 (2.3)
4 (3.1)
5 (3.8)
3 (2.3)
3 (2.3)
3 (2.3)
2 (1.5)
1 (0.8)
2 (1.5)
2 (1.5)
2 (1.5)

15
0
0
0
0
0
0
4
0
0
0
0
0
0
0
0
0
1
0
0
0
0
0
2
0
0
0
0
1
0
0
0
0

(11.5)

(3.1)

(0.8)

(1.5)

(0.8)

Note: TRAEs include those with possible, probable, or missing relationship to any study drug.

ADA to vopratelimab across phase I and phase II were detected in
up to 24.5% of patients with vopratelimab monotherapy and up to
34.5% of patients with vopratelimab plus nivolumab. Treatmentboosted ADAs were detected in up to 2.7% of patients treated with
vopratelimab monotherapy and up to 8.0% of patients treated with
vopratelimab plus nivolumab. The frequency of neutralizing ADA
was lower: up to 8.1% with vopratelimab monotherapy and up to
13.8% with the combination. There was no apparent difference
between vopratelimab pharmacokinetic parameters determined by
noncompartmental analysis for patients with and without ADA,
and a concentration–response relationship between vopratelimab
exposure and target engagement was established. The RP2D of
vopratelimab, 0.3 mg/kg every 3 weeks, was selected because it did
not exceed the MTD and resulted in concentrations that achieved or
exceeded concentrations necessary to achieve complete receptor
occupancy (deﬁned as >70% binding of ICOS) throughout the
dosing interval (Supplementary Fig. S3).
Pharmacokinetics of vopratelimab þ nivolumab
Nivolumab was administered at 240 mg i.v. every 3 weeks; this dose
schedule was investigational at the time the study was open and
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coincided with that of vopratelimab. Where applicable, the maximum
observed concentration (Cmax) and AUC of nivolumab over the ﬁrst
14 days of cycle 1 are presented in Supplementary Table S2. Nivolumab
AUC values over the ﬁrst 14 days after administration were comparable with previously reported values (18), and there was no apparent
effect of vopratelimab coadministration on nivolumab Cmax or AUC.
Likewise, nivolumab had no apparent effect on the cycle 1 pharmacokinetics of vopratelimab.
Preliminary efﬁcacy
The efﬁcacy of vopratelimab, both as monotherapy and in combination with nivolumab, was evaluated for all tumors, as well as each of
the four tumor-speciﬁc cohorts in phase II (gastric cancer, NSCLC,
HNSCC, and TNBC), overall and according to baseline tumor ICOS
IHC and PD-L1 scores. Preliminary efﬁcacy results (Table 3) represent
all patients with these tumor types from phase I (n ¼ 57) and phase II
(n ¼ 110). Vopratelimab monotherapy demonstrated a conﬁrmed
investigator-assessed RECIST v1.1 partial response (PR) in 1 patient
with advanced gastric cancer who was PD-(L)1 na€ve. Vopratelimab in
combination with nivolumab demonstrated conﬁrmed RECIST v1.1
PRs in 2 of 35 patients with advanced gastric cancer [5.7%; 17% PD-(L)
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Patients with at least one TRAE
Nausea
Fatigue
Infusion-related reaction
Decreased appetite
Chills
Pyrexia
Aspartate aminotransferase increased
Diarrhea
Pruritus
Rash
Arthralgia
Vomiting
Constipation
Myalgia
Alanine aminotransferase increased
Headache
Rash maculopapular
Anemia
Blood alkaline phosphatase increased
Cough
Dizziness
Dyspnea
Hyponatremia
Hypothyroidism
Asthenia
Musculoskeletal pain
Weight decreased
Abdominal pain
Dehydration
Dry mouth
Dry skin
Flushing

Vopratelimab monotherapy
N ¼ 70 (%)
Grade 1 and 2
Grade ≥3
n (%)
n (%)

3701

Abbreviations: DCR, disease control rate - conﬁrmed CR or PR þ stable disease lasting at least 53 days; HNSCC, head and neck squamous cell carcinoma; NE, not estimable; NSCLC, non–small cell lung cancer; ORR, overall
response rate - conﬁrmed CR or PR; PD-(L)1i, PD-(L)1 inhibitor; TNBC, triple-negative breast cancer.

7.5 (1.8–10.8) 5.7 (3.1–9.8) 3.4 (2.3–11.2) 12.3 (6.3–16.9) 7.3 (1.7–7.7) 7.8 (4.6–11.3) 9.2 (4.9–9.2) 10.9 (6.2–15.8) 7.5 (3.9–10.5) 12.2 (6.6–13.2) 7.5 (4.9–9.2) 9.0 (7.2–11.7)

30 (22.9)
2 (1.9–2.0)
7 (29.2)
2 (1.8–3.9)
11 (31.4%)
2.1 (1.8–3.1)
2 (20.0%)
2.1 (0.7–3.5)

0
1.9 (1.4–2.2)

5 (29.4%)
1.9 (1.7–3.4)

1 (12.5%)
2.1 (1.3-NE)

4 (13.8%)
1.8 (1.3–2.0)

2 (33.3%)
2 (1.1–2.1)

3 (11.5%)
2 (1.8–2.1)

5 (12.8)
2 (1.9–2.1)

10 (14.3)
2 (1.9–2.1)

131
65
3 (2.3%)
70
30
1 (1.4%)
24
10
0
39
14
0
26
26
0
6
6
0
29
6
1 (3.4%)
8
1
0
17
17
0
7
7
0
35
6
2 (5.7%)

Vopra þ nivo Vopra
Vopra
Vopra

10
2
1 (10.0%)

Patients, n
Prior PD-(L)1i, n
PRþCR [# patients
(ORR)]
DCR, n (%)
Median PFS
(months) (95%
CI)
Median OS
(months)
(95% CI)

Vopra þ nivo Vopra
Vopra

Vopra þ nivo Vopra

Other
HNSCC

TNBC
Vopra þ
nivo
NSCLC

Gastric
Vopra þ
nivo
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1 inhibitor experienced] and in 1 of 29 (3.4%) patients with advanced
TNBC [21% PD-(L)1 inhibitor experienced]; all responders were PD(L)1 na€ve, and each of these responses were highly durable: 1 for
almost 3.5 years; 2 are ongoing after 4 years. No RECIST v1.1 responses
were observed with monotherapy or combination therapy in patients
with other tumors or PD-(L)1 inhibitor experienced HNSCC or
NSCLC (Supplementary Fig. S4). The median PFS for the total
population was 2.0 months (95% CI, 1.9–2.1 for vopratelimab monotherapy; 95% CI, 1.9–2.0 for vopratelimab in combination with
nivolumab). The median OS for the entire population was 7.5 months
(95% CI, 4.9–9.2) for those in the vopratelimab monotherapy group
and 9.0 months (95% CI, 7.2–11.7) in the combination group (Table 3;
Supplementary Fig. S5). In both treatment groups, there were no
apparent associations of clinical outcomes with either ICOS IHC or
PD-L1 IHC in the baseline tumor (Supplementary Table S3).
Identiﬁcation of a vopratelimab-speciﬁc pharmacodynamic
biomarker
To investigate mechanisms underlying the clinical outcomes,
PBMC samples were analyzed from a subset of 44 patients who had
both longitudinal PBMC samples with sufﬁcient viable cells and were
evaluable for efﬁcacy, including the 4 responders. This analysis of
cellular changes by ﬂow cytometry identiﬁed a potential pharmacodynamic biomarker of ICOS agonistic effects in peripheral blood,
ICOS-hi CD4 T cells, and its association with clinical outcomes was
evaluated.
Patients who displayed on-treatment emergence of ICOS-hi CD4
T cells had signiﬁcantly greater clinical beneﬁt from treatment than
those who did not (Fig. 1). The objective response rate (ORR) in
patients with ICOS-hi CD4 T-cell emergence was 4/20 (20%),
compared with 0 of 24 (0%) in ICOS-lo patients (P ¼ 0.0357).
Median PFS in the ICOS-hi CD4 T-cell group was 6.2 months
(95% CI, 3.4–19.6) compared with 1.9 months (95% CI, 1.8–2.1;
P < 0.001) in the ICOS-lo group, and the median OS reached
20.7 months (95% CI, 9.1–not estimable) in the ICOS-hi group but
was only 9.0 months (95% CI, 5.4–13.6; P ¼ 0.0025) in the ICOS-lo
group. These differences are not explained by patients’ clinical
baseline characteristics, which were evenly distributed across both
groups (Supplementary Table S4).
Representative ﬂow cytometry analysis shows that a patient who
achieved a conﬁrmed RECIST v1.1 PR demonstrated emergence of
ICOS-hi CD4 T cells, while one patient with conﬁrmed RECIST v1.1
stable disease initially demonstrated the emergence of ICOS-hi CD4
T cells, but subsequently demonstrated loss of this cell population
upon radiological progression (Supplementary Fig. S6A). Moreover,
in a patient with best response of radiological progressive disease, no
emergence was observed in peripheral blood (Supplementary
Fig. S6A).
Although ICOS can also be upregulated on CD8 T cells, an ICOS-hi
CD8 population was not detected, suggesting a CD4-focused mechanism of action for vopratelimab (Supplementary Fig. S6B). ICOS-hi
CD4 T cells were present within the peripheral CD4 compartment at
high levels and persisted over the course of treatment in patients with
conﬁrmed RECIST v1.1 PR to vopratelimab monotherapy or in
combination with nivolumab (n ¼ 4; Supplementary Fig. S6C).
To conﬁrm that the observed ICOS-hi CD4 T-cell emergence
was a vopratelimab-speciﬁc response [and not a PD-(L)1 inhibitor
response], a companion phenotyping study was performed in
77 patients with advanced NSCLC (N ¼ 64) and melanoma
(N ¼ 12) treated with commercially available PD-1 or PD-L1
inhibitor monotherapy, and included 6 radiological responders (19).
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Table 3. Preliminary efﬁcacy of vopratelimab as monotherapy or in combination with nivolumab (phase I and phase II) data cutoff: 07-22-2020.

All/Total
Vopra þ
nivo

Yap et al.

The ICOS Agonist Vopratelimab Alone and with Nivolumab

The emergence of ICOS-hi CD4 T cells was not observed at any
on-treatment timepoint over the 6-month period assessed in any
of these patients treated with single-agent PD-(L)1 inhibitors, as
seen in the representative ﬂow cytometry histogram analyses from
responding patients with NSCLC in Supplementary Fig. S6D and
S6E, respectively (19).
Characterization of peripheral ICOS-hi CD4 T cells
Further characterization of the 44 patients on the ICONIC trial
with serially collected pretreatment and on-treatment PBMC samples and efﬁcacy assessments demonstrated that the peripheral
ICOS-hi CD4 T cells were enriched in certain CD4 T-cell subsets,
including Th1, T central memory (Tcm), and follicular Th cells
(Tfh), but not in regulatory T cells. In the subset of patients with
emergence of the ICOS-hi CD4 T-cell population, sustained proliferation of these cells as measured by Ki-67 expression was
observed with vopratelimab alone or in combination with nivolumab. This suggests a CD4-centric mechanism (Supplementary
Fig. S7A), as only an early CD8 proliferation signal was identiﬁed,
consistent with nivolumab pharmacodynamic activity (20). Gene
expression analysis of CD4 T cells from ICOS-hi responders to
vopratelimab in combination with nivolumab compared with
ICOS-lo CD4 T cells from representative patients with cancer
showed that gene expression proﬁles were signiﬁcantly different
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between these groups (FDR-adjusted P value <0.05). As a bulk
population, ICOS-hi CD4 T cells were more likely to express genes
associated with cytotoxic function (perforin and granzymes), and
effector T-cell activation (Supplementary Fig. S7B and S7D). Additional phenotypic proﬁling demonstrated no enrichment of regulatory T cells within the ICOS-hi CD4 T-cell population as cells
were negative for CD25 and FOXP3 (Supplementary Fig. S7C).
Further ﬂow proﬁling demonstrated enrichment of subsets, including Th1, Tcm, and Tfh, which were represented as relatively
equivalent fractions of the CD4 compartment (Supplementary
Fig. S7D).
Identifying a predictive biomarker of response to vopratelimab
The association between a vopratelimab-speciﬁc pharmacodynamic
biomarker (emergence of ICOS-hi CD4 T cells) and clinical beneﬁt
enabled a focused assessment of predictive biomarkers of response to
determine whether baseline characteristics could predict for ICOS-hi
CD4 T-cell emergence and therefore select for the patient population
that may beneﬁt most from vopratelimab. Various biomarkers in
baseline tumor tissue were evaluated for their ability to predict the
emergence of a peripheral ICOS-hi CD4 T-cell population in response
to vopratelimab with or without nivolumab. In baseline tumor tissue,
neither ICOS IHC nor PD-L1 IHC were found to predict the emergence of a peripheral ICOS-hi CD4 T-cell population in response to
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Figure 1.
Pharmacodynamic biomarker ICOS-hi CD4 T-cell emergence correlates with response and improvements in OS and PFS. A retrospective analysis was performed on
44 patients who had both evaluable longitudinal PBMC samples and were evaluable for efﬁcacy. In all panels, patients who have ICOS-hi CD4 T-cell emergence at any
timepoint are depicted in purple; patients without ICOS-hi CD4 T-cell emergence at any time are depicted in blue. A, Waterfall plot reﬂecting individual patients’
maximum reduction in the sum of diameters of target tumors compared with baseline in patients with at least one postbaseline CT scan (n ¼ 42). Not all patients with
≥ 30% tumor reductions are RECIST PR. B, Patients with emergence of ICOS-hi CD4 T cells had improved responses, PFS, and OS as compared with patients without
emergence of this pharmacodynamic biomarker. C, Kaplan–Meier curve demonstrates improved PFS in ICOS-hi versus ICOS-lo patients. D, Kaplan–Meier curve
demonstrating the OS beneﬁt for patients with ICOS-hi CD4 T-cell emergence as compared with patients who are ICOS-lo. Data cutoff for all panels is July 22, 2020.
ICOS, inducible costimulator; ICOS-hi, patients with an emergent CD4 T-cell population with high levels of ICOS; ICOS-lo, patients without the emergence of a CD4
T-cell population expressing high levels of ICOS; PFS, progression-free survival; ORR, overall response rate; OS, overall survival; NE, not estimable.
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vopratelimab monotherapy or in combination with nivolumab (Supplementary Fig. S8). However, using NanoString’s nCounter proﬁling
of RNA isolated from pretreatment tumor biopsies (n ¼ 89), an
association was found between the TIS gene expression score (21)
and emergence of ICOS-hi CD4 T cells in the 27 patients who had data
for both TIS score and ICOS. The 18 TIS genes, originally demonstrated as predictive of response to anti-PD-1 therapy (16), are
associated with IFNg signaling, antigen presentation, lymphocyte
and monocyte abundance, and activation of CD4 T cells and other
immune cells (Fig. 2A). Because vopratelimab activity requires the
presence of activated CD4 T cells (14), the genes included in TIS are
highly relevant to vopratelimab. Patients with treatment-emergent
ICOS-hi CD4 T cells had a higher median TIS score (N ¼ 12, 7.9)
than those in the ICOS-lo group (N ¼ 15, 6.7; P ¼ 0.0031, two-sided
Wilcoxon two-sample exact test). ROC curve analysis determined
that TIS was predictive for the emergence of ICOS-hi CD4 T cells
(n ¼ 27; AUC ¼ 0.83; Fig. 2B). The optimal TIS threshold of
7.9 (TISvopra) for predicting this TIS-driven PD response (emergence of an ICOS-hi CD4 T-cell population) was calculated using
the Youden index to optimize sensitivity and speciﬁcity. TISvopra
has a positive predictive value of 89% and a negative predictive
value of 78% for the emergence of the cell population.
An analysis of the correlation of TISvopra with efﬁcacy was done on
89 patients for whom TISvopra data were available (n ¼ 29 received
vopratelimab, n ¼ 60 received vopratelimab þ nivolumab). Patients
treated with vopratelimab alone and in combination with nivolumab
with TISvopra-positive baseline tumor samples had better outcomes to
treatment compared with those with TISvopra-negative tumor samples
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including RECIST responses, a higher PFS rate at 6 months and
median OS. Speciﬁcally, radiological target lesion tumor reduction
was greater in patients with TISvopra-positive tumors versus those with
TISvopra-negative tumors (Fig. 3A); the ORR in TISvopra-positive
patients was 14.3% (3/21; TIS score was not obtained for the 1
responder to vopratelimab monotherapy) compared with 0.0% (0/
62) in TISvopra-negative (P ¼ 0.0145; Supplementary Table S4). In
addition, patients in the TISvopra-positive group remained on treatment longer than those in the TISvopra-negative group (Fig. 3B); mean
(SD) treatment duration of 7.8 months (10.40) with a range of 1.2–
34.8 months in TISvopra-positive versus 2.3 months (1.61) with a range
of 0.2–7.9 months in the TISvopra-negative group (P ¼ 0.0205). Median
PFS was 2.2 months (95% CI, 2.0–4.6 months) for TISvopra-positive
patients (n ¼ 22) compared with 1.9 months (95% CI, 1.8–2.0 months)
for TISvopra-negative patients (n ¼ 67; Fig. 3C); the P value for PFS
comparison of TISvopra-positive versus TISvopra-negative patients is
0.0002 using log-rank test, suggesting signiﬁcant overall risk reduction
in disease progression or death for the TISvopra-positive patients. The
probability of being progression free at 6 months was 21.1% (95% CI,
6.6–41.1) for TISvopra-positive patients compared with 3.8% (95% CI,
0.7–11.4) for TISvopra-negative patients, P < 0.0001. The PFS rate at
9 months was 21.1% (95% CI, 6.6–41.1) for TISvopra-positive patients,
while all TISvopra-negative patients discontinued prior to 9 months. An
improvement was also seen in median OS, which was 16.9 months
(95% CI, 9.1–21.4 months) for TISvopra-positive patients (n ¼ 22)
compared with 6.2 months (95% CI, 3.7–9.0 months) for TISvopranegative patients (n ¼ 67), P ¼ 0.0062 (Fig. 3D). Finally, OS rate at
12 months since ﬁrst dose was 60.7% (95% CI, 34.4–79.1) for TISvopra-
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Figure 2.
Identifying TIS as a biomarker for the emergence of ICOS-hi CD4 T cells and calculating a threshold for TISvopra. Various tumor biomarkers were evaluated for their
ability to predict the emergence of a peripheral ICOS-hi CD4 T-cell population in response to vopratelimab monotherapy or with nivolumab. A, The 18 TIS genes are
associated with antigen presentation, lymphocyte abundance, IFN activity, and T-cell exhaustion, including activation of CD4 T cells. Genes highlighted in blue
are involved in antigen presentation to CD4 T cells (HLA-DRB1 and HLA-DQA1) and successful recruitment of T cells and antigen-presenting cells (CCL5 and CXCL9).
B, ROC curve demonstrating the ability of TIS to predict ICOS-hi CD4 T-cell emergence (n ¼ 27, AUC ¼ 0.83) and the lack of prediction by PD-L1 IHC (n ¼ 24,
AUC ¼ 0.55). AUC, area under the curve; ICOS, inducible costimulator; IHC, immunohistochemistry; PD-L1, programmed death-ligand 1; ROC, receiver operating
characteristic; TIS, tumor inﬂammation signature.
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positive patients compared with 25.1% (95% CI, 14.4–37.3) for
TISvopra-negative patients, P < 0.0001. Although the TISvopra threshold
was developed to predict emergence of ICOS-hi CD4 T cells and
not OS, an additional analysis of OS was done excluding the 27
patients whose data was used to determine the TISvopra threshold. A
similar trend was observed: TISvopra-positive patients (N ¼ 13)
demonstrated prolonged survival with a median OS of 9.9 versus
4.9 months in TISvopra-negative patients (N ¼ 49), P ¼ 0.3055
(Supplementary Fig. S9).

Discussion
The ICOS pathway has gained great interest in oncology as it plays
an important role in memory and effector T-cell development and
speciﬁc humoral immune responses; thus ICOS agonist antibodies
have emerged as an active class of investigational immunotherapy
agents, with multiple agents currently in clinical trial development
(22). Data from chimeric Ag receptors (CAR) with ICOS intracellular
binding domains demonstrated improved efﬁcacy in solid tumor
models due to an increase in persistence of CD4þ and CD8þ CAR
T cells and effector function important for durable remissions, suggesting an important role for ICOS agonism in durability of response
(22, 23). The ICONIC phase I/II study is the ﬁrst trial to assess the
safety, pharmacokinetics, pharmacodynamics, preliminary efﬁcacy
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and predictive biomarkers of response to vopratelimab, an ICOS
agonist mAb, alone and in combination with nivolumab in a heavily
pretreated patient population.
Vopratelimab was well tolerated and did not impact the safety
proﬁle of nivolumab. Selection of the RP2D (0.3 mg/kg every 3 weeks)
was based on sustained TE throughout the dosing period as well as
safety and pharmacokinetic data. ADAs were observed, but there was
no apparent difference between vopratelimab pharamcokinetic parameters determined by noncompartmental analysis for patients with
and without ADA, and a concentration–response relationship between
vopratelimab exposure and target engagement was established. Taken
together, these data indicate that the level of ADA observed most likely
did not affect the activity of vopratelimab in this study.
Treatment with vopratelimab alone or in combination with nivolumab did not result in signiﬁcant tumor reductions. The signiﬁcance
of this study lies in the hypothesis-testing, reverse translational
approach, in which blood and tumor samples were collected from
patients and analyzed for biomarkers that correlated with clinical
outcomes. This led to the identiﬁcation of a peripheral blood pharmacodynamic biomarker, treatment-emergent ICOS-hi CD4 T cells,
that provided clinical evidence of the mechanism of action of vopratelimab and was associated with clinical beneﬁt. Emergence and
persistence of this pharmacodynamic biomarker conﬁrmed that agonism of ICOS by vopratelimab results in the proliferation and sustained

Clin Cancer Res; 28(17) September 1, 2022

Downloaded from http://aacrjournals.org/clincancerres/article-pdf/28/17/3695/3199454/3695.pdf by Washington University St Louis user on 30 October 2022

Figure 3.
TISvopra predicts tumor regression and clinical beneﬁt. ICONIC patients treated with vopratelimab monotherapy or in combination with nivolumab who had
pretreatment tumor samples that were TISvopra positive showed better outcomes to treatment than those whose tumor samples were TISvopra negative. In all panels,
orange depicts TISvopra-positive patients and gray shows TISvopra-negative patients. A, Waterfall plot showing maximum reduction in the sum of diameters of target
tumors compared with baseline in patients with at least one postbaseline CT scan who were assessed for TISvopra status (n ¼ 67). B, Swimmer plots showing time on
treatment for patients who were evaluated for TISvopra (n ¼ 89). Arrows indicate patients for whom treatment is ongoing. Left, Patients who are TISvopra positive;
right, patients who are TISvopra negative. BOR is evaluated using RECIST 1.1; PR is depicted in green, stable disease is depicted in yellow, PD is depicted black, NE is
depicted in gray. C, PFS curves for TISvopra-positive versus TISvopra-negative patients, as evaluated by investigator review. An event is deﬁned as PD or death (see
Patients and Methods). D, OS curves for TISvopra-positive versus TISvopra-negative patients. An event is deﬁned as death (see Patients and Methods). BOR, best overall
response; CR, complete response; ICOS, inducible costimulator; PD, progressive disease; PR, partial response; RECIST, response evaluation criteria in solid tumors;
SD, stable disease; TIS, tumor inﬂammation signature. Data cutoff for all panels is July 22, 2020.
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activation of ICOS-hi CD4 T cells, which include Th1, Tcm, and Tfh
subsets. The combined functions of these T-cell subsets support the
role of vopratelimab in eliciting both direct and durable antitumor
responses of patients: Th1 cells possess direct antitumor activity, Tfh
cells support B cell and cytotoxic CD8 activity, and perhaps most
importantly, Tcm cells may contribute to the long durability of the
antitumor responses. The emergence and persistence of these T cells in
patients with advanced cancers beneﬁting from an ICOS agonist
supports the role of ICOS in generating a comprehensive and durable
immune response to cancer.
Also noteworthy, the pharmacodynamic biomarker has isolated
the effects of vopratelimab from the combination partner nivolumab, a PD-1 inhibitor, enabling a vopratelimab-speciﬁc approach
for the identiﬁcation of the potential predictive biomarker of response, TISvopra. TIS includes genes involved in CD4 T-cell activation and has been shown to be predictive for response to PD-1
inhibitors using different thresholds (16, 21, 24). The threshold
determined in this study for TISvopra is based on prediction of
ICOS- hi CD4 T-cell emergence, thereby presumably exploiting
prediction for PD-1 inhibition, and importantly, optimizing it
directly as a predictor of the CD4 focused mechanism of action
of vopratelimab. Application of TISvopra to the ICONIC data
demonstrated a statistically signiﬁcant improvement in clinical outcomes for TISvopra-positive patients compared with patients below
the threshold. TIS has been evaluated and shown not to be prognostic in most cancers, including gastric (21, 25), supporting its use
as a predictive biomarker for vopratelimab-based therapy. While
not all patients will beneﬁt from immunotherapy, we hypothesize
that utilization of a predictive biomarker for vopratelimab will
identify patients in whom the therapeutic mechanism is most
relevant, potentially resulting in durable clinical beneﬁt in such
patients. The ability of the TISvopra biomarker signature to identify
patients most likely to beneﬁt from the combination of vopratelimab and a PD-1 inhibitor is currently being tested prospectively
in a randomized phase II trial of vopratelimab plus an investigational PD-1 inhibitor JTX-4014 (pimivalimab), versus JTX-4014
alone in patients with PD-(L)1 inhibitor–na€ve NSCLC (SELECT,
NCT04549025). More broadly, the concept of identifying and utilizing a treatment-emergent pharmacodynamic biomarker to enable
an expanded identiﬁcation of patients for predictive biomarker
assessments may lead to an improved means of matching the right
immunotherapy with the right patient.
Limitations of the study include the low tumor response rates
observed, the small number of samples evaluated for peripheral and
tissue-based biomarker studies, as well as the retrospective and
prospective analysis of peripheral blood samples. However, the identiﬁcation of both the pharmacodynamic biomarker, treatmentemergent ICOS-hi CD4 T cells and the potential predictive biomarker,
TISvopra, are intriguing ﬁndings that have led to the current clinical
development program of vopratelimab, and may also be applicable to
other ICOS agonists in clinical development. We believe that such a
biomarker-driven strategy in early clinical drug development is necessary for the successful optimization of immunotherapy combinations, particularly as clinical approaches involving novel agents with
PD-(L)1 inhibitors in broader molecularly unselected populations of
patients have largely not been met with success.
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